| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
20054 |
| Drug |
Carfilzomib (in combination with daratumumab and dexamethasone) |
| Brand |
Kyprolis® |
| Indication |
In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Rapid review commissioned |
08/12/2020 |
| Rapid review completed |
14/01/2021 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of carfilzomib in combination with daratumumab and dexamethasone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/01/2021 |
| Pre-submission consultation with Applicant |
12/10/2021 |
| Full submission received from Applicant |
17/07/2023 |
